The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study

References

• Athyros VG, Papageorgiou AA, Mercouris BR, Athyrou VV, Symeonidis AN, Basayannis EO, Demitriadis DS, Kontopoulos AG. Treatment with atorvastatin to the National Cholesterol Educational Program goals versus usual care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Curr Med Res Opin 2002;4:220–28
   Google Scholar
• EUROASPIRE Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE-II Euro Heart Survey Programme. Eur Heart J 2001;22:554–72
   PubMed Web of Science ®Google Scholar
• Brady AJ, Oliver MA, Pittard JB. Secondary prevention in 24,431 patients with coronary heart disease: survey in primary care. BMJ 2001;322: 1463
   PubMed Web of Science ®Google Scholar
• Schwartz GG, Olsson AG, Ezekowitz MD et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. JAMA 2001;285:1711–8
   PubMed Web of Science ®Google Scholar
• Smilde TJ, van Wissen S, Wollerstein H, Trip MD, Kastelein JJP, Stahlenhoef AFH. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001;357:577–81
   PubMed Web of Science ®Google Scholar
• Pitt B, Waters D, Brown WV, van Boven AJ, Schwartz L, Title LM, Eisenberg D, Shurzinske L and McCormick LS for the Atorvastatin versus Revascularization Treatment Investigators. Aggressive lipid-lowering compared with angioplasty in stable coronary artery disease. N Engl J Med 1999;341:70–76
   Google Scholar
• Mikhailidis DP, Wierzbicki AS, Reynolds TM. Is a mechanical or a metabolic approach superior in the treatment of coronary disease? Results of the atorvastatin versus revascularization (AVERT) trial. Eur Heart J 2001;22:972
   PubMed Web of Science ®Google Scholar
• Wierzbicki AS, Crook MA, Reynolds TM, Mikhailidis DP. Measurement of atherosclerosis progression. Lancet 2001;358:329–30
   PubMed Web of Science ®Google Scholar
• Wierzbicki AS, Mikhailidis DP, Reynolds TM. Atorvastatin for acute coronary syndromes. JAMA 2001;286:532–3
   PubMed Web of Science ®Google Scholar
• Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high density lipoprotein cholesterol level: a meta-analysis of the population-based prospective studies. J Cardiovasc Risk 1996;3:213–9
   PubMedGoogle Scholar
• Boden WE, Pearson TA. Raising low levels of high-density lipoprotein cholesterol is an important target of therapy. Am J Cardiol 2000;85:645–9
   PubMed Web of Science ®Google Scholar
• Rubins HB, Robins SJ, Collins D et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999;341:410–17
   PubMed Web of Science ®Google Scholar
• Rizos E, Mikhailidis DP. Are high-density lipoprotein and triglyceride levels important in secondary prevention? Impressions from the BIP and VA-HIT trials. Int J Cardiol 2002;82:199–207
   PubMed Web of Science ®Google Scholar
• Wierzbicki AS, Mikhailidis DP. Beyond LDL-C – the importance of raising HDL-C. Curr Med Res Opin 2002;18:36–44
   PubMed Web of Science ®Google Scholar
• Mikhailidis DP, Wierzbicki AS. HDL-cholesterol and the treatment of coronary heart disease: contrasting effects of atorvastatin and simvastatin. Curr Med Res Opin 2000;16:139–46
   PubMed Web of Science ®Google Scholar
• Mikhailidis DP, Wierzbicki AS. Editorial Comment: Attaining United States and European Guideline LDL-C cholesterol Levels with simvastatin in patients with coronary heart disease (the GOALLS study). Curr Med Res Opin 2000;16:205–7
   PubMed Web of Science ®Google Scholar
• Rizos E, Mikhailidis DP. Are high density lipoprotein (HDL) and triglyceride levels relevant in stroke prevention? Cardiovasc Res 2001;52:199–207
   PubMed Web of Science ®Google Scholar
• Papadakis JA, Mikhailidis DP, Winder AF. Lipids and stroke: neglect of a useful preventive measure? Cardiovasc Res 1998;40:265–71
   Google Scholar
• Heart Protection Study. http://www.ctsu.ox.ac.uk/~hps/
   Google Scholar
• Crouse JR 3rd, Byington RP, Furberg CD. HMG-CoA reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trials data. Atherosclerosis 1998;138: 11–24
   PubMed Web of Science ®Google Scholar
• Tobacco or health. A global status report. World Health Organization, Geneva, 1997
   Google Scholar
• Cheng K-S, Mikhailidis DP, Hamilton G, Seifalian AM. The carotid and femoral intima-media thickness (IMT): are they predictors of peripheral vascular disease and cardiovascular risk factors? Cardiovasc Res 2002; in press
   Google Scholar
• Davis M, Atwal AS, Nair DR, Jagroop IA, Seifalian AS, Mikhailidis DP, Hamilton G. The effect of short term lipid lowering with atorvastatin on carotid artery intima media thickness in patients with peripheral vascular disease: a pilot study. Curr Med Res Opin 2000;16:198–204
   PubMed Web of Science ®Google Scholar
• Youssef F, Seifalian AM, Jagroop A, Myint F, Baker D, Mikhailidis DP, Hamilton G. The early effect of lipid-lowering treatment on carotid and femoral intima media thickness (IMT). Eur J Vasc Endovasc Surg 2002; in press
   PubMed Web of Science ®Google Scholar
• Borghi C, Veronesi M, Prandin MG, Dormi A, Ambrosini E. Statins and blood pressure regulation. Curr Hypertens Rep 2001;3:281–8
   PubMedGoogle Scholar
• Glorioso N, Troffa C, Filigheddu F, Dettori F, Soro A, Parpaglia PP, Collatina S, Pahor M. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension 1999;34:1281–6
   PubMed Web of Science ®Google Scholar
• Tonolo G, Melis MG, Formato M, Angius MF, Carboni A, Brizzi P et al. Additive effects of simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients. Eur J Clin Invest 2000;30:980–87
   PubMed Web of Science ®Google Scholar
• Malhotra HS, Goa KL. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia. Drugs 2001;12:1835–81
   Google Scholar
• Wood D, Durrington P, Poulter N, McInnes G, Rees A, Wray R on behalf of the Societies. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 1998;80(Suppl 2):S1–S29
   PubMedGoogle Scholar
• Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the national cholesterol education program(NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001;285:2486–97
   PubMed Web of Science ®Google Scholar
• Wierzbicki AS, Crook MA, Nair DR, Mikhailidis DP, Winder AF. More on the effect of atorvastatin on plasma fibrinogen levels in primary hypercholesterolaemia. Atherosclerosis 2000;148:204
   PubMed Web of Science ®Google Scholar
• Kolovou G. The treatment of coronary heart disease: statins beyond cholesterol lowering. Curr Med Res Opin 2001;17:34–7
   PubMed Web of Science ®Google Scholar
• Goudevenos JA, Bairaktari ET, Chatzidimou KG, Milionis HJ, Mikhailidis DP, Elisaf MS. The effect of atorvastatin on serum lipids, lipoprotein(a) and plasma fibrinogen levels in primary dyslipidaemia – a pilot study involving serial sampling. Curr Med Res Opin 2000;16:269–75
   Web of Science ®Google Scholar
• Maison P, Mennen L, Sapinho D et al. for the D.E.S.I.R. study group. A pharmacological assessment of the effect of statins and fibrates on fibrinogen concentration. Atherosclerosis 2002;160:155–60
   PubMed Web of Science ®Google Scholar
• Song JC, White CM. Do HMG-CoA reductase inhibitors affect fibrinogen? Ann Pharmacother 2001;35:236–41
   PubMed Web of Science ®Google Scholar
• Wierzbicki AS, Lumb PJ, Chik G, Crook MA. Fibrinogen response with simvastatin versus atorvastatin in familial hypercholesterolemia. Am J Cardiol 2001;87:338–40
   PubMed Web of Science ®Google Scholar
• Cromwell WC, Ziajka PE. Development of tachyphylaxis among patients taking HMG CoA reductase inhibitors. Am J Cardiol 2000;86:1123–7
   PubMed Web of Science ®Google Scholar
• Wierzbicki AS, Mikhailidis DP. Dose response effects of atorvastatin and simvastatin on high-density lipoprotein cholesterol in hypercholesterolaemic patients: a review of five comparative studies. Int J Cardiol 2002; in press
   PubMed Web of Science ®Google Scholar
• Garmendia F, Brown AS, Reiber I, Adams PC. Attaining United States and European guideline LDL-cholesterol levels with simvastatin in patients with coronary heart disease (the GOALLS study). Curr Med Res Opin 2000;16:208–19
   PubMed Web of Science ®Google Scholar
• Seed M, Weir MR for the International Quality of Life Multicenter Group. Double-masked comparison of the quality of life of hypercholesterolemic men treated with simvastatin or pravastatin. Clin Ther 1999;21:1758–70
   PubMed Web of Science ®Google Scholar
• Phillips C, Smith R, Pittard J. Secondary prevention with statin therapy: a budgetary-impact assessment for UK primary care. J Med Econ 2000;3:21–33
   Google Scholar
• Karalis DG, Ross AM, Vacari RM, Zarren H, Scott R. Comparison of efficacy and safety of atorvastatin and simvastatin in patients with dyslipidemia with and without coronary heart disease. Am J Cardiol 2002;89:667–71
   PubMed Web of Science ®Google Scholar